Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute-On-Chronic Liver Failure | 16 | 2024 | 64 | 6.860 |
Why?
|
Carcinoma, Hepatocellular | 21 | 2025 | 931 | 5.270 |
Why?
|
Liver Neoplasms | 22 | 2025 | 1313 | 4.810 |
Why?
|
Liver Cirrhosis | 31 | 2025 | 831 | 3.960 |
Why?
|
End Stage Liver Disease | 9 | 2023 | 181 | 3.240 |
Why?
|
Liver Transplantation | 16 | 2024 | 1038 | 2.490 |
Why?
|
Fatty Liver | 10 | 2013 | 184 | 2.170 |
Why?
|
Non-alcoholic Fatty Liver Disease | 17 | 2023 | 395 | 2.080 |
Why?
|
Liver Diseases | 3 | 2024 | 366 | 1.770 |
Why?
|
Early Detection of Cancer | 4 | 2025 | 361 | 1.730 |
Why?
|
Hepatitis C | 3 | 2023 | 366 | 1.600 |
Why?
|
Hepatitis C, Chronic | 3 | 2021 | 325 | 1.210 |
Why?
|
Humans | 97 | 2025 | 124703 | 1.010 |
Why?
|
Postal Service | 1 | 2024 | 9 | 0.940 |
Why?
|
Patient Navigation | 1 | 2024 | 25 | 0.910 |
Why?
|
Graft Survival | 3 | 2024 | 536 | 0.830 |
Why?
|
Isoflavones | 1 | 2022 | 45 | 0.790 |
Why?
|
Severity of Illness Index | 14 | 2023 | 2895 | 0.780 |
Why?
|
Prognosis | 11 | 2024 | 4626 | 0.780 |
Why?
|
Duodenal Diseases | 2 | 2019 | 34 | 0.770 |
Why?
|
Gastroparesis | 1 | 2022 | 67 | 0.750 |
Why?
|
Mass Screening | 2 | 2025 | 782 | 0.720 |
Why?
|
Exercise Therapy | 1 | 2022 | 153 | 0.700 |
Why?
|
Frailty | 1 | 2022 | 106 | 0.680 |
Why?
|
Telemedicine | 2 | 2023 | 434 | 0.670 |
Why?
|
Quality of Life | 5 | 2022 | 1935 | 0.670 |
Why?
|
Prevalence | 12 | 2021 | 2447 | 0.640 |
Why?
|
Alcohol Drinking | 3 | 2021 | 343 | 0.640 |
Why?
|
Palliative Care | 2 | 2020 | 428 | 0.640 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2019 | 80 | 0.630 |
Why?
|
Organ Transplantation | 1 | 2021 | 167 | 0.630 |
Why?
|
Lipase | 4 | 2020 | 93 | 0.620 |
Why?
|
Syphilis | 1 | 2019 | 96 | 0.620 |
Why?
|
Penicillins | 1 | 2019 | 155 | 0.610 |
Why?
|
Publication Bias | 1 | 2018 | 14 | 0.610 |
Why?
|
Endoscopy, Digestive System | 1 | 2019 | 149 | 0.600 |
Why?
|
Probiotics | 2 | 2018 | 214 | 0.590 |
Why?
|
Risk Assessment | 6 | 2025 | 3447 | 0.570 |
Why?
|
Antiviral Agents | 5 | 2025 | 750 | 0.530 |
Why?
|
Observational Studies as Topic | 3 | 2023 | 88 | 0.530 |
Why?
|
Testosterone | 1 | 2021 | 533 | 0.510 |
Why?
|
Membrane Proteins | 5 | 2020 | 1532 | 0.510 |
Why?
|
Irritable Bowel Syndrome | 1 | 2018 | 206 | 0.490 |
Why?
|
Sodium | 3 | 2020 | 295 | 0.480 |
Why?
|
Anxiety | 2 | 2023 | 941 | 0.470 |
Why?
|
Eosinophilic Esophagitis | 1 | 2015 | 75 | 0.440 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 1270 | 0.440 |
Why?
|
Ascites | 3 | 2024 | 88 | 0.440 |
Why?
|
Middle Aged | 27 | 2025 | 26796 | 0.430 |
Why?
|
Aged | 21 | 2025 | 19763 | 0.420 |
Why?
|
Deglutition Disorders | 1 | 2015 | 132 | 0.410 |
Why?
|
Protein Phosphatase 1 | 1 | 2013 | 51 | 0.410 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2022 | 97 | 0.390 |
Why?
|
Vitamin D Deficiency | 1 | 2013 | 74 | 0.390 |
Why?
|
United States | 15 | 2024 | 10897 | 0.390 |
Why?
|
Depression | 1 | 2020 | 1223 | 0.380 |
Why?
|
Vitamin D | 1 | 2013 | 161 | 0.380 |
Why?
|
Retrospective Studies | 22 | 2024 | 16325 | 0.360 |
Why?
|
Treatment Outcome | 12 | 2025 | 12354 | 0.360 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2013 | 539 | 0.360 |
Why?
|
Cross-Sectional Studies | 8 | 2022 | 3430 | 0.360 |
Why?
|
Male | 31 | 2025 | 61264 | 0.360 |
Why?
|
Reproducibility of Results | 2 | 2015 | 2877 | 0.350 |
Why?
|
Cohort Studies | 8 | 2022 | 4803 | 0.330 |
Why?
|
United States Department of Veterans Affairs | 3 | 2024 | 672 | 0.330 |
Why?
|
Gastrointestinal Microbiome | 4 | 2024 | 700 | 0.330 |
Why?
|
Organ Dysfunction Scores | 2 | 2020 | 48 | 0.330 |
Why?
|
Polymorphism, Genetic | 1 | 2013 | 812 | 0.330 |
Why?
|
Inflammation | 1 | 2017 | 1431 | 0.320 |
Why?
|
Hepacivirus | 2 | 2021 | 243 | 0.320 |
Why?
|
Helicobacter pylori | 3 | 2024 | 1319 | 0.320 |
Why?
|
Liver | 6 | 2021 | 1738 | 0.320 |
Why?
|
Helicobacter Infections | 3 | 2024 | 1263 | 0.320 |
Why?
|
Diet | 3 | 2022 | 1138 | 0.320 |
Why?
|
Ultrasonography | 5 | 2021 | 929 | 0.310 |
Why?
|
Chemoembolization, Therapeutic | 2 | 2019 | 24 | 0.310 |
Why?
|
Biopsy | 4 | 2023 | 1237 | 0.310 |
Why?
|
Hepatitis, Alcoholic | 3 | 2021 | 26 | 0.310 |
Why?
|
Colon | 3 | 2021 | 349 | 0.300 |
Why?
|
Gastroesophageal Reflux | 2 | 2024 | 295 | 0.300 |
Why?
|
Gastroenterology | 2 | 2025 | 196 | 0.290 |
Why?
|
Health Services Accessibility | 2 | 2024 | 607 | 0.290 |
Why?
|
Female | 28 | 2025 | 66557 | 0.280 |
Why?
|
Secondary Prevention | 2 | 2020 | 217 | 0.280 |
Why?
|
Myotomy | 2 | 2017 | 19 | 0.280 |
Why?
|
Nutrition Surveys | 5 | 2020 | 293 | 0.270 |
Why?
|
Alcohol Abstinence | 2 | 2017 | 16 | 0.270 |
Why?
|
Adult | 22 | 2023 | 29481 | 0.270 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2022 | 304 | 0.260 |
Why?
|
Risk Factors | 13 | 2025 | 10284 | 0.260 |
Why?
|
Intestinal Mucosa | 3 | 2021 | 776 | 0.250 |
Why?
|
Bacteria | 2 | 2019 | 484 | 0.240 |
Why?
|
Immunotherapy | 2 | 2022 | 673 | 0.240 |
Why?
|
Weight Loss | 3 | 2023 | 483 | 0.230 |
Why?
|
Paracentesis | 1 | 2024 | 17 | 0.230 |
Why?
|
Virus Activation | 1 | 2025 | 87 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 1111 | 0.230 |
Why?
|
Hernia, Hiatal | 1 | 2024 | 55 | 0.230 |
Why?
|
Esophageal and Gastric Varices | 2 | 2023 | 65 | 0.220 |
Why?
|
Tissue Donors | 3 | 2022 | 494 | 0.220 |
Why?
|
Fundoplication | 1 | 2024 | 65 | 0.220 |
Why?
|
Liver Diseases, Alcoholic | 2 | 2021 | 57 | 0.220 |
Why?
|
Hepatitis B virus | 1 | 2025 | 130 | 0.220 |
Why?
|
Allografts | 2 | 2021 | 191 | 0.220 |
Why?
|
Herniorrhaphy | 1 | 2024 | 82 | 0.220 |
Why?
|
Hepatic Encephalopathy | 2 | 2023 | 75 | 0.220 |
Why?
|
Hypertension, Portal | 2 | 2024 | 78 | 0.220 |
Why?
|
Gastroenterologists | 1 | 2023 | 11 | 0.210 |
Why?
|
Early Diagnosis | 1 | 2024 | 181 | 0.210 |
Why?
|
Disease Progression | 4 | 2024 | 2049 | 0.210 |
Why?
|
Hepatitis B | 1 | 2025 | 159 | 0.210 |
Why?
|
Bacterial Infections | 2 | 2016 | 309 | 0.210 |
Why?
|
Morbidity | 1 | 2023 | 247 | 0.200 |
Why?
|
Anti-Obesity Agents | 1 | 2022 | 41 | 0.200 |
Why?
|
Plasma Exchange | 1 | 2023 | 84 | 0.200 |
Why?
|
Hemochromatosis | 1 | 2022 | 32 | 0.200 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 2050 | 0.200 |
Why?
|
Physical Fitness | 1 | 2022 | 90 | 0.190 |
Why?
|
Anti-Bacterial Agents | 3 | 2024 | 2428 | 0.190 |
Why?
|
Genetic Pleiotropy | 1 | 2021 | 24 | 0.190 |
Why?
|
Genome-Wide Association Study | 3 | 2021 | 1684 | 0.180 |
Why?
|
Biliary Atresia | 1 | 2024 | 190 | 0.180 |
Why?
|
Hospital Mortality | 2 | 2024 | 1024 | 0.180 |
Why?
|
Referral and Consultation | 1 | 2024 | 541 | 0.180 |
Why?
|
Global Burden of Disease | 1 | 2021 | 26 | 0.180 |
Why?
|
Bacterial Translocation | 2 | 2024 | 24 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 1140 | 0.180 |
Why?
|
Biomarkers | 3 | 2024 | 3066 | 0.170 |
Why?
|
Precancerous Conditions | 1 | 2023 | 282 | 0.170 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 443 | 0.170 |
Why?
|
Health Care Costs | 1 | 2023 | 371 | 0.170 |
Why?
|
Esophageal Achalasia | 2 | 2017 | 37 | 0.170 |
Why?
|
Acute Kidney Injury | 3 | 2024 | 633 | 0.170 |
Why?
|
Abdominal Cavity | 1 | 2019 | 8 | 0.160 |
Why?
|
Hyperkalemia | 1 | 2021 | 66 | 0.160 |
Why?
|
Treponema pallidum | 1 | 2019 | 49 | 0.160 |
Why?
|
Patient Care Planning | 1 | 2020 | 121 | 0.160 |
Why?
|
Tissue and Organ Procurement | 1 | 2022 | 224 | 0.160 |
Why?
|
Serologic Tests | 1 | 2019 | 118 | 0.160 |
Why?
|
Mutation | 2 | 2022 | 5825 | 0.160 |
Why?
|
Mortality | 1 | 2020 | 238 | 0.150 |
Why?
|
Patient Reported Outcome Measures | 1 | 2020 | 172 | 0.150 |
Why?
|
Ablation Techniques | 1 | 2018 | 31 | 0.150 |
Why?
|
Hemochromatosis Protein | 2 | 2022 | 22 | 0.140 |
Why?
|
Lymph Nodes | 1 | 2019 | 382 | 0.140 |
Why?
|
Esophageal Sphincter, Lower | 1 | 2017 | 11 | 0.140 |
Why?
|
Dietary Supplements | 1 | 2021 | 476 | 0.140 |
Why?
|
Stomach Neoplasms | 1 | 2023 | 545 | 0.140 |
Why?
|
Esophagitis, Peptic | 1 | 2017 | 33 | 0.140 |
Why?
|
Time Factors | 5 | 2021 | 6308 | 0.140 |
Why?
|
Radiosurgery | 1 | 2018 | 109 | 0.140 |
Why?
|
Transition to Adult Care | 1 | 2019 | 119 | 0.140 |
Why?
|
Pancreatitis, Acute Necrotizing | 1 | 2016 | 4 | 0.140 |
Why?
|
Ileus | 1 | 2016 | 9 | 0.130 |
Why?
|
Alcohol-Related Disorders | 1 | 2017 | 34 | 0.130 |
Why?
|
Hepatitis, Viral, Human | 1 | 2017 | 44 | 0.130 |
Why?
|
Self Expandable Metallic Stents | 1 | 2016 | 7 | 0.130 |
Why?
|
Case-Control Studies | 4 | 2023 | 3284 | 0.130 |
Why?
|
Patient Selection | 1 | 2020 | 695 | 0.130 |
Why?
|
Esophageal Diseases | 1 | 2016 | 35 | 0.130 |
Why?
|
Colorectal Neoplasms | 1 | 2022 | 574 | 0.130 |
Why?
|
Stomach Diseases | 1 | 2016 | 57 | 0.130 |
Why?
|
Patient Discharge | 1 | 2019 | 490 | 0.120 |
Why?
|
Colectomy | 1 | 2016 | 74 | 0.120 |
Why?
|
Appendectomy | 1 | 2016 | 85 | 0.120 |
Why?
|
Prosthesis Failure | 1 | 2016 | 158 | 0.120 |
Why?
|
Prebiotics | 1 | 2015 | 23 | 0.120 |
Why?
|
Terminology as Topic | 1 | 2017 | 222 | 0.120 |
Why?
|
Computer Simulation | 1 | 2018 | 646 | 0.120 |
Why?
|
Genotype | 3 | 2022 | 2556 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 3154 | 0.120 |
Why?
|
Intubation, Gastrointestinal | 1 | 2015 | 52 | 0.120 |
Why?
|
Suture Techniques | 1 | 2016 | 196 | 0.120 |
Why?
|
Endoscopy | 1 | 2017 | 280 | 0.120 |
Why?
|
Hospitalization | 2 | 2024 | 1779 | 0.120 |
Why?
|
Mexican Americans | 2 | 2013 | 204 | 0.120 |
Why?
|
Predictive Value of Tests | 2 | 2017 | 2155 | 0.120 |
Why?
|
Veterans | 3 | 2024 | 1757 | 0.120 |
Why?
|
Gene Frequency | 2 | 2013 | 722 | 0.110 |
Why?
|
Anxiety Disorders | 1 | 2020 | 672 | 0.110 |
Why?
|
Population Surveillance | 1 | 2017 | 388 | 0.110 |
Why?
|
Statistics as Topic | 1 | 2015 | 256 | 0.110 |
Why?
|
Surveys and Questionnaires | 2 | 2023 | 3716 | 0.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 732 | 0.110 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 1883 | 0.110 |
Why?
|
Patient Care Team | 1 | 2018 | 541 | 0.110 |
Why?
|
Pancreatitis | 1 | 2015 | 130 | 0.110 |
Why?
|
Young Adult | 7 | 2019 | 9022 | 0.110 |
Why?
|
Colitis, Ulcerative | 1 | 2016 | 205 | 0.110 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2015 | 154 | 0.100 |
Why?
|
Aged, 80 and over | 3 | 2021 | 6548 | 0.100 |
Why?
|
Preoperative Care | 1 | 2015 | 356 | 0.100 |
Why?
|
Contraceptives, Oral | 1 | 2012 | 37 | 0.100 |
Why?
|
Enteral Nutrition | 1 | 2015 | 256 | 0.100 |
Why?
|
Menstruation | 1 | 2012 | 29 | 0.100 |
Why?
|
Hyperuricemia | 1 | 2013 | 37 | 0.100 |
Why?
|
Prospective Studies | 5 | 2023 | 6147 | 0.100 |
Why?
|
Sepsis | 1 | 2017 | 478 | 0.100 |
Why?
|
Uric Acid | 1 | 2013 | 94 | 0.100 |
Why?
|
alpha-Fetoproteins | 2 | 2023 | 132 | 0.090 |
Why?
|
Cognition Disorders | 1 | 2016 | 553 | 0.090 |
Why?
|
Obesity | 2 | 2022 | 2244 | 0.090 |
Why?
|
Cognition | 1 | 2016 | 722 | 0.090 |
Why?
|
Length of Stay | 3 | 2024 | 1311 | 0.090 |
Why?
|
Incidence | 1 | 2018 | 3140 | 0.090 |
Why?
|
Waiting Lists | 2 | 2021 | 227 | 0.080 |
Why?
|
Biomedical Research | 1 | 2015 | 519 | 0.080 |
Why?
|
Genetic Association Studies | 1 | 2013 | 778 | 0.080 |
Why?
|
Asia | 2 | 2021 | 107 | 0.080 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 1662 | 0.080 |
Why?
|
Pancreatic Neoplasms | 1 | 2015 | 691 | 0.080 |
Why?
|
RNA, Ribosomal, 16S | 2 | 2021 | 369 | 0.080 |
Why?
|
Europe | 2 | 2020 | 353 | 0.070 |
Why?
|
Adenocarcinoma | 1 | 2015 | 1023 | 0.070 |
Why?
|
Genetic Variation | 1 | 2013 | 1497 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2017 | 5160 | 0.070 |
Why?
|
Pilot Projects | 2 | 2022 | 1391 | 0.060 |
Why?
|
Endoscopy, Gastrointestinal | 2 | 2017 | 241 | 0.060 |
Why?
|
Databases, Factual | 2 | 2021 | 1177 | 0.050 |
Why?
|
Natural Orifice Endoscopic Surgery | 1 | 2024 | 64 | 0.050 |
Why?
|
Bevacizumab | 1 | 2023 | 64 | 0.050 |
Why?
|
Gastroscopy | 1 | 2023 | 100 | 0.050 |
Why?
|
Policy | 1 | 2023 | 35 | 0.050 |
Why?
|
Diethylpropion | 1 | 2022 | 2 | 0.050 |
Why?
|
Phentermine | 1 | 2022 | 7 | 0.050 |
Why?
|
Liraglutide | 1 | 2022 | 14 | 0.050 |
Why?
|
Delayed Diagnosis | 1 | 2024 | 126 | 0.050 |
Why?
|
Research Design | 2 | 2020 | 693 | 0.050 |
Why?
|
Bupropion | 1 | 2022 | 28 | 0.050 |
Why?
|
Neurocan | 2 | 2013 | 2 | 0.050 |
Why?
|
Chondroitin Sulfate Proteoglycans | 2 | 2013 | 27 | 0.050 |
Why?
|
Naltrexone | 1 | 2022 | 70 | 0.050 |
Why?
|
Metaplasia | 1 | 2023 | 213 | 0.050 |
Why?
|
Donor Selection | 1 | 2022 | 55 | 0.050 |
Why?
|
Prothrombin | 1 | 2022 | 25 | 0.050 |
Why?
|
Hydrogels | 1 | 2022 | 82 | 0.050 |
Why?
|
Lectins, C-Type | 2 | 2013 | 71 | 0.050 |
Why?
|
Ferritins | 1 | 2022 | 97 | 0.050 |
Why?
|
Interrupted Time Series Analysis | 1 | 2021 | 24 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2023 | 419 | 0.050 |
Why?
|
Verrucomicrobia | 1 | 2021 | 14 | 0.050 |
Why?
|
Sex Factors | 2 | 2017 | 1286 | 0.050 |
Why?
|
Health Care Rationing | 1 | 2021 | 58 | 0.050 |
Why?
|
Meta-Analysis as Topic | 1 | 2021 | 156 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2025 | 634 | 0.040 |
Why?
|
Simvastatin | 1 | 2021 | 76 | 0.040 |
Why?
|
Patient Readmission | 1 | 2024 | 385 | 0.040 |
Why?
|
Syndrome | 1 | 2023 | 1119 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2020 | 56 | 0.040 |
Why?
|
Heterozygote | 1 | 2022 | 671 | 0.040 |
Why?
|
Cost of Illness | 1 | 2021 | 249 | 0.040 |
Why?
|
Colonoscopy | 1 | 2022 | 236 | 0.040 |
Why?
|
Necrosis | 1 | 2020 | 208 | 0.040 |
Why?
|
Overweight | 1 | 2022 | 364 | 0.040 |
Why?
|
Food Analysis | 1 | 2019 | 26 | 0.040 |
Why?
|
Fibrosis | 1 | 2021 | 431 | 0.040 |
Why?
|
Survival Rate | 1 | 2024 | 2045 | 0.040 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2021 | 225 | 0.040 |
Why?
|
Attitude | 1 | 2019 | 115 | 0.040 |
Why?
|
Aftercare | 1 | 2019 | 147 | 0.040 |
Why?
|
Comorbidity | 1 | 2023 | 1531 | 0.040 |
Why?
|
Renal Insufficiency | 1 | 2021 | 236 | 0.040 |
Why?
|
Communication | 1 | 2022 | 516 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2022 | 1251 | 0.040 |
Why?
|
Risk | 1 | 2020 | 755 | 0.040 |
Why?
|
Adolescent | 3 | 2024 | 19278 | 0.040 |
Why?
|
DNA, Bacterial | 1 | 2019 | 478 | 0.040 |
Why?
|
Feces | 1 | 2021 | 728 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2020 | 2634 | 0.040 |
Why?
|
Exercise | 1 | 2023 | 817 | 0.030 |
Why?
|
Consensus | 1 | 2020 | 645 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2017 | 83 | 0.030 |
Why?
|
Disease Management | 1 | 2020 | 524 | 0.030 |
Why?
|
Healthcare Disparities | 1 | 2021 | 431 | 0.030 |
Why?
|
Nerve Tissue Proteins | 2 | 2013 | 1111 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2016 | 2092 | 0.030 |
Why?
|
Sutures | 1 | 2016 | 65 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 1090 | 0.030 |
Why?
|
Tertiary Care Centers | 1 | 2017 | 235 | 0.030 |
Why?
|
Intraabdominal Infections | 1 | 2015 | 2 | 0.030 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2015 | 12 | 0.030 |
Why?
|
Psychomotor Performance | 1 | 2016 | 182 | 0.030 |
Why?
|
Pandemics | 1 | 2022 | 1102 | 0.030 |
Why?
|
Computational Biology | 1 | 2019 | 811 | 0.030 |
Why?
|
Biomarkers, Tumor | 1 | 2022 | 1486 | 0.030 |
Why?
|
Lysophospholipase | 1 | 2013 | 1 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 1037 | 0.030 |
Why?
|
Recurrence | 1 | 2017 | 1421 | 0.030 |
Why?
|
Survival Analysis | 1 | 2016 | 1498 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2013 | 81 | 0.030 |
Why?
|
Kidney | 1 | 2019 | 1358 | 0.030 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2013 | 115 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2013 | 156 | 0.020 |
Why?
|
Phenotype | 1 | 2021 | 4255 | 0.020 |
Why?
|
Sampling Studies | 1 | 2011 | 77 | 0.020 |
Why?
|
Liver Function Tests | 1 | 2011 | 100 | 0.020 |
Why?
|
Child | 2 | 2024 | 24371 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 285 | 0.020 |
Why?
|
Urinary Tract Infections | 1 | 2015 | 302 | 0.020 |
Why?
|
Smoking | 1 | 2016 | 1046 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 870 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2011 | 288 | 0.020 |
Why?
|
Odds Ratio | 1 | 2013 | 1258 | 0.020 |
Why?
|
Infant | 1 | 2024 | 12471 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2011 | 1435 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 1356 | 0.020 |
Why?
|
Logistic Models | 1 | 2013 | 1810 | 0.020 |
Why?
|
Blood Glucose | 1 | 2011 | 1136 | 0.020 |
Why?
|
Age Factors | 1 | 2013 | 2819 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2011 | 875 | 0.020 |
Why?
|
Insulin | 1 | 2011 | 1203 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 3556 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2017 | 3071 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 1622 | 0.010 |
Why?
|